Browse HLA-DOB

Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Note=Complexes with HLA-DM molecule during intracellular transport and in endosomal/lysosomal compartments. Heterotetramerization is necessary to exit the ER.
Domain PF07654 Immunoglobulin C1-set domain
PF00969 Class II histocompatibility antigen
Function

Important modulator in the HLA class II restricted antigen presentation pathway by interaction with the HLA-DM molecule in B-cells. Modifies peptide exchange activity of HLA-DM.

> Gene Ontology
 
Biological Process GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0002577 regulation of antigen processing and presentation
GO:0002578 negative regulation of antigen processing and presentation
GO:0002580 regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0002581 negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0002583 regulation of antigen processing and presentation of peptide antigen
GO:0002584 negative regulation of antigen processing and presentation of peptide antigen
GO:0002586 regulation of antigen processing and presentation of peptide antigen via MHC class II
GO:0002587 negative regulation of antigen processing and presentation of peptide antigen via MHC class II
GO:0002683 negative regulation of immune system process
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0048002 antigen processing and presentation of peptide antigen
Molecular Function GO:0003823 antigen binding
GO:0023023 MHC protein complex binding
GO:0023026 MHC class II protein complex binding
GO:0032395 MHC class II receptor activity
Cellular Component GO:0005765 lysosomal membrane
GO:0010008 endosome membrane
GO:0042611 MHC protein complex
GO:0042613 MHC class II protein complex
GO:0044440 endosomal part
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
hsa04514 Cell adhesion molecules (CAMs)
hsa04612 Antigen processing and presentation
hsa04640 Hematopoietic cell lineage
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-2132295: MHC class II antigen presentation
Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HLA-DOB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HLA-DOB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HLA-DOB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1650.413
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2590.621
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0920.808
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3110.648
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2180.837
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4410.739
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.810.209
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2080.201
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3120.753
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5210.199
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4290.406
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0040.988
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HLA-DOB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HLA-DOB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HLA-DOB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HLA-DOB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HLA-DOB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HLA-DOB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HLA-DOB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHLA-DOB
Namemajor histocompatibility complex, class II, DO beta
Aliases DOB; MHC class II antigen DOB; HLA class II histocompatibility antigen, DO beta chain
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HLA-DOB collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.